# A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG)

Source: https://onco.cc/trials/nct06211764/  
OnCo record `nct06211764` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Gemcitabine intravesical system (TAR-200), Mitomycin C and Gemcitabine in bladder & urothelial cancer, run by Janssen Research & Development, LLC, active and no longer recruiting.

## Summary

A Study of TAR-200 Versus Intravesical Chemotherapy in Participants With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer (HR-NMIBC) After Bacillus Calmette-Guérin (BCG) is a phase 3 interventional study registered as NCT06211764 by Janssen Research & Development, LLC, with 272 participants enrolled, started 2024-04-09 and due to reach its primary completion in 2030-11-27. Interventions recorded: TAR-200, Mitomycin C and Gemcitabine.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06211764
- Phase: 3
- Setting: 17000139BLC3004: 17000139BLC3004 [SunRISe-5] Ph III HR NMIBC BCG Exp/UR Pap (N=250)
- Sponsor: Janssen Research & Development, LLC
- Enrolled: 272

## Sources

- ClinicalTrials.gov NCT06211764: https://clinicaltrials.gov/study/NCT06211764

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- drugs: [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Gemcitabine intravesical system (TAR-200)](https://onco.cc/drugs/tar-200/), [Mitomycin C](https://onco.cc/drugs/mitomycin/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/)

---
JSON: https://onco.cc/api/v1/entities/nct06211764.json